Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gini F Fleming

Showing results (71-80 of 180) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Phase I study of an oral formulation of ZD9331 administered daily for 28 daysMichael B Sawyer, Mark J Ratain, Donna Bertucci, et al.
Gynecologic Oncology|January 21, 2018
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignanciesHeidi J Gray, Katherine Bell-McGuinn, Gini F Fleming, et al.
Plos One|January 21, 2016
Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with ChemotherapyObiageli Ezewuiro, Tatyana A Grushko, Masha Kocherginsky, et al.
Gynecologic Oncology|April 22, 2008
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II ConsortiaHalla S Nimeiri, Amit M Oza, Robert J Morgan, et al.
Cancer Chemotherapy and Pharmacology|April 27, 2002
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracilDale R Shepard, Sridhar Mani, Helen Kastrissios, et al.
Gynecologic Oncology|February 2, 2010
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II ConsortiaHalla S Nimeiri, Amit M Oza, Robert J Morgan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group StudyGini F Fleming, Virginia L Brunetto, David Cella, et al.
Cancer|November 20, 2009
Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group StudyJohn H Farley, Chunqiao Tian, G Scott Rose, et al.
Gynecologic Oncology|September 21, 2017
Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesionsIngvild L Tangen, Jennifer Taylor Veneris, Mari K Halle, et al.
Cancer Chemotherapy and Pharmacology|February 20, 2007
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancerWei Peng Yong, Apurva A Desai, Federico Innocenti, et al.
Pageof 18

Showing results (71-80 of 180) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2003
Phase I study of an oral formulation of ZD9331 administered daily for 28 daysMichael B Sawyer, Mark J Ratain, Donna Bertucci, et al.
Gynecologic Oncology|January 21, 2018
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignanciesHeidi J Gray, Katherine Bell-McGuinn, Gini F Fleming, et al.
Plos One|January 21, 2016
Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with ChemotherapyObiageli Ezewuiro, Tatyana A Grushko, Masha Kocherginsky, et al.
Gynecologic Oncology|April 22, 2008
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II ConsortiaHalla S Nimeiri, Amit M Oza, Robert J Morgan, et al.
Cancer Chemotherapy and Pharmacology|April 27, 2002
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracilDale R Shepard, Sridhar Mani, Helen Kastrissios, et al.
Gynecologic Oncology|February 2, 2010
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II ConsortiaHalla S Nimeiri, Amit M Oza, Robert J Morgan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group StudyGini F Fleming, Virginia L Brunetto, David Cella, et al.
Cancer|November 20, 2009
Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group StudyJohn H Farley, Chunqiao Tian, G Scott Rose, et al.
Gynecologic Oncology|September 21, 2017
Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesionsIngvild L Tangen, Jennifer Taylor Veneris, Mari K Halle, et al.
Cancer Chemotherapy and Pharmacology|February 20, 2007
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancerWei Peng Yong, Apurva A Desai, Federico Innocenti, et al.
Pageof 18